MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/pas.0000000000002513

Медицинская библиотека · The American journal of surgical pathology · 2026

Metatypic Carcinoma of the Pancreas: Delineation of a Clinicopathologically Distinct Entity, Characterized by Centrally Necrotic Demarcated High-Grade Carcinoma With Divergent Patterns, Basal Immunophenotype, and Altered Molecular Profile.

Atasoy Duygu, Saka Burcu, Armutlu Ayse, Mericoz Cisel A, Bagci Pelin, Balci Serdar, Tezcan Nuray, Bakkaloglu Irem G, Altinmakas Emre, Bozkurt Emre, Pehlivanoglu Burcin, Bozkurtlar Emine, Alper Emrah, Luchini Claudio, Mafficini Andrea, Bevere Michele, Scarpa Aldo, Tellioglu Gurkan, Yilmaz Serpil, Bilge Orhan, Esmer Rohat, Cheng Jeanette D, Tarcan Zeynep, Basturk Olca, Reid Michelle D, Krasinskas Alyssa, Gurses Bengi, Adsay N Volkan

СтатьяПеревод пока не подготовлен

Аннотация

A distinct type of pancreatic carcinoma (n=31; 6% of adenocarcinomas) is described, distinguished from conventional pancreatic ductal adenocarcinoma (PDAC) by: (1) solid/undifferentiated (sheet-like, stroma-poor) carcinomas lacking features of other entities (no osteoclasts, microsatellite stable, INI-1 retained, nonkeratinizing squamous <30%), often admixed with ordinary PDAC; (2) radiology/gross showing central necrosis/demarcation mimicking nonductal neoplasms, not scirrhous like PDAC; (3) marked intratumoral heterogeneity with divergent patterns, including basal/squamoid (81%), solid sheets punctuated with megavacuoles (77%), clear cell (68%), mucoepidermoid-like (36%), sarcomatoid (36%), and occasional choriocarcinomatous or angiosarcomatous patterns, and some with carcinomatous vasculitis; (4) cellular anaplasia with pleomorphic giant cells (55%), multinucleated nonosteoclastic (32%), and rhabdoid-like (32%); (5) immunohistochemically (n=16) consistently showing a basal phenotype with common GATA6 loss/depletion and/or CK5/6, p40, or p63 expression; (6) molecular-genetic profile (n=13) showing altered frequencies: ARID1A (31% vs. 4%) and CDKN2A/p16 (92% vs. 30%) alterations, universal KRAS mutations with enrichment in KRAS G12D, frequent TP53, and lower SMAD4 loss (8% vs. 55%). Limited follow-up suggests comparable or more favorable outcomes. In conclusion, this is a distinct type of carcinoma in the pancreas that is prone to being misdiagnosed as nonductal/non-PDAC cancers. It is the first pancreatic carcinoma type in which a basal molecular phenotype can be indicated clinically by both imaging and histopathology, with major potential management implications (as it is also enriched in actionable targets like ARID1A). Recognition of this category is critical for cancer research, as it offers an invaluable group to study plasticity, stroma versatility, necrosis mechanisms, and the basal type in pancreatic cancer.

Для цитирования: Atasoy Duygu, Saka Burcu, Armutlu Ayse, Mericoz Cisel A, Bagci Pelin, Balci Serdar, Tezcan Nuray, Bakkaloglu Irem G, Altinmakas Emre, Bozkurt Emre, Pehlivanoglu Burcin, Bozkurtlar Emine, Alper Emrah, Luchini Claudio, Mafficini Andrea, Bevere Michele, Scarpa Aldo, Tellioglu Gurkan, Yilmaz Serpil, Bilge Orhan, Esmer Rohat, Cheng Jeanette D, Tarcan Zeynep, Basturk Olca, Reid Michelle D, Krasinskas Alyssa, Gurses Bengi, Adsay N Volkan. Metatypic Carcinoma of the Pancreas: Delineation of a Clinicopathologically Distinct Entity, Characterized by Centrally Necrotic Demarcated High-Grade Carcinoma With Divergent Patterns, Basal Immunophenotype, and Altered Molecular Profile.. The American journal of surgical pathology. 2026. DOI: 10.1097/pas.0000000000002513.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.